Department of Chemistry, University of Basel, Klingelbergstrasse 80, CH-4056 Basel, Switzerland.
Acc Chem Res. 2011 Oct 18;44(10):1039-49. doi: 10.1021/ar200036k. Epub 2011 May 24.
One strategy in modern medicine is the development of new platforms that combine multifunctional compounds with stable, safe carriers in patient-oriented therapeutic strategies. The simultaneous detection and treatment of pathological events through interactions manipulated at the molecular level offer treatment strategies that can decrease side effects resulting from conventional therapeutic approaches. Several types of nanocarriers have been proposed for biomedical purposes, including inorganic nanoparticles, lipid aggregates, including liposomes, and synthetic polymeric systems, such as vesicles, micelles, or nanotubes. Polymeric vesicles--structures similar to lipid vesicles but created using synthetic block copolymers--represent an excellent candidate for new nanocarriers for medical applications. These structures are more stable than liposomes but retain their low immunogenicity. Significant efforts have been made to improve the size, membrane flexibility, and permeability of polymeric vesicles and to enhance their target specificity. The optimization of these properties will allow researchers to design smart compartments that can co-encapsulate sensitive molecules, such as RNA, enzymes, and proteins, and their membranes allow insertion of membrane proteins rather than simply serving as passive carriers. In this Account, we illustrate the advances that are shifting these molecular systems from simple polymeric carriers to smart-complex protein-polymer assemblies, such as nanoreactors or synthetic organelles. Polymeric vesicles generated by the self-assembly of amphiphilic copolymers (polymersomes) offer the advantage of simultaneous encapsulation of hydrophilic compounds in their aqueous cavities and the insertion of fragile, hydrophobic compounds in their membranes. This strategy has permitted us and others to design and develop new systems such as nanoreactors and artificial organelles in which active compounds are simultaneously protected and allowed to act in situ. In recent years, we have created a variety of multifunctional, proteinpolymersomes combinations for biomedical applications. The insertion of membrane proteins or biopores into the polymer membrane supported the activity of co-encapsulated enzymes that act in tandem inside the cavity or of combinations of drugs and imaging agents. Surface functionalization of these nanocarriers permitted specific targeting of the desired biological compartments. Polymeric vesicles alone are relatively easy to prepare and functionalize. Those features, along with their stability and multifunctionality, promote their use in the development of new theranostic strategies. The combination of polymer vesicles and biological entities will serve as tools to improve the observation and treatment of pathological events and the overall condition of the patient.
在现代医学中,一种策略是开发新的平台,将多功能化合物与稳定、安全的载体相结合,应用于以患者为中心的治疗策略中。通过在分子水平上操纵相互作用,同时检测和治疗病理事件,提供了可以减少传统治疗方法副作用的治疗策略。已经提出了几种类型的纳米载体用于生物医学目的,包括无机纳米粒子、脂质聚集体,包括脂质体,以及合成聚合物系统,如囊泡、胶束或纳米管。聚合物囊泡——与脂质体类似但使用合成嵌段共聚物创建的结构——是用于医学应用的新型纳米载体的极佳候选物。这些结构比脂质体更稳定,但保留了低免疫原性。已经做出了重大努力来改善聚合物囊泡的尺寸、膜的灵活性和通透性,并增强其靶向特异性。这些特性的优化将使研究人员能够设计智能隔室,这些隔室可以共同封装敏感分子,如 RNA、酶和蛋白质,并且它们的膜允许插入膜蛋白,而不仅仅是作为被动载体。在本报告中,我们说明了将这些分子系统从简单的聚合物载体转变为智能复杂的蛋白质-聚合物组装体,如纳米反应器或合成细胞器的进展。由两亲性嵌段共聚物(聚合物囊泡)自组装产生的聚合物囊泡具有同时将亲水性化合物封装在其水腔中和将易碎的疏水性化合物插入其膜中的优点。该策略使我们和其他人能够设计和开发新的系统,如纳米反应器和人工细胞器,其中活性化合物同时被保护并允许在原位作用。近年来,我们为生物医学应用创建了各种多功能、蛋白质-聚合物囊泡组合。将膜蛋白或生物孔插入聚合物膜中,支持共同封装的酶在腔内串联作用的活性,或药物和成像剂的组合。这些纳米载体的表面功能化允许对所需生物隔室进行特异性靶向。聚合物囊泡本身相对容易制备和功能化。这些特性,以及它们的稳定性和多功能性,促进了它们在新的治疗策略开发中的应用。聚合物囊泡与生物实体的结合将作为工具,用于改善对病理事件的观察和治疗以及患者的整体状况。